The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation

The Impact of Cyp4f2 Polymorphism on The Safety Profile And Regime Dosing of Phenindion In Patients With Valvular Atrial Fibrillation

Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.

Saved in:
Bibliographic Details
Published in:Clinical therapeutics Vol. 37; no. 8; p. e24
Main Authors: Shakhidzhanova, V.S, Sychev, D.A, Kazаkov, R.E, Grishenko, N.D, Palamarchuk, Y.Y, Kossovskaya, A.V, Tretyakov, A.Y
Format: Journal Article
Language:English
Published: Bridgewater Elsevier Inc 01-08-2015
Elsevier Limited
Subjects:
Anticoagulants
Genotype & phenotype
Internal Medicine
Medical Education
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction In the reason of FDA prohibition in using of "new" oral anticoagulants, vitamin K antagonists have become uncontested drugs to the patients with valvular atrial fibrillation.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.075